Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Pfizer Hikes U.S. Prices for More Than 100 Drugs on Jan. 1

Deena Beasley  |  

Also in 2014 the company, currently headquartered in New York, spent $8.4 billion on research and development, $14.1 billion on sales, informational and administrative costs, including advertising, and nearly $12 billion to buy back its shares and pay dividends to shareholders.

Related Articles

    Pfizer to Buy Allergan in $160 Billion Deal

    NEW YORK (Reuters)—Pfizer Inc. on Monday said it would buy Botox maker Allergan Plc. in a deal worth $160 billion to slash its U.S. tax bill, rekindling a fierce political debate over the financial maneuver. The acquisition, which would shift Pfizer’s headquarters to Ireland, would be the biggest-ever tax inversion. The news prompted Democratic presidential…

    U.S. Tribal Patent Deal Could Impact Generic Drug Market

    (Reuters)—A groundbreaking deal between Allergan Plc. and a Native American tribe to shield the company’s patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts say, potentially dealing a blow to generic competition. Allergan said on Friday it had transferred patents on its blockbuster dry eye…

    U.S. Supreme Court Rejects Allergan Bid to Use Tribe to Shield Drug Patents

    WASHINGTON (Reuters)—The U.S. Supreme Court has cast aside pharmaceutical company Allergan Plc.’s unorthodox bid to shield patents from a federal administrative court’s review by transferring them to a Native American tribe. The justices left in place a lower court ruling upholding the authority of a U.S. Patent and Trademark Office tribunal to decide the validity…